Edwards Lifesciences Corporation · NYSE:EW
Edwards Lifesciences — 39th Annual J.P. Morgan Healthcare Conference (January 2021)
25 slides from Edwards Lifesciences's conference presentation, Jan 11, 2021
Slide 1: Edwards Lifesciences
Edwards Lifesciences 39th Annual J.P. Morgan Healthcare Conference January 11, 2021
Slide 2: Cautionary Statement
Cautionary Statement This video presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as “may,” “wi
Slide 3: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures Unless otherwise indicated, all figures are GAAP financial measures. The Company uses the term "adjusted sales" or “underlying growth rate” when referring to non-GAAP sales information, which excludes foreign exchange rate fluctuations, the conversion to a consignm
Slide 4: Our Credo
Our Credo Through our actions, we will become trusted partners with customers, colleagues, and patients – creating a community unified in its mission to improve the quality of life around the world. Our results will benefit customers, patients, employees and shareholders. We will celebrate our succe
Slide 5: Helping Patients Around the World
Helping Patients Around the World 94% 97% Sales from Employees consider products with what’s important to #1 global market patients when making share decisions 15,000+ Global employees (50%+ Millennials 7 and Generation Z) ~2,000 Manufacturing Engineers 80%+ facilities around the world Charitable em
Slide 6: Patient-Focused Innovation Strategy
Patient-Focused Innovation Strategy Focus Singular focus on the large unmet needs of structural heart and critically ill patients Create Leadership Meaningful Innovation Lead groundbreaking Value by Pioneer breakthrough standards of care Transforming technologies with through trusted Patient Care co
Slide 7: $10B + by 2025
Edwards’ patient-focused innovation strategy has produced sustained underlying sales growth Global Transcatheter Opportunity Focused on opportunities where $10B+ by 2025 patient demand is very large Edwards Sales $4.9 - $5.3 ($ in billions) $4.3 $3.4 $3.7 Long-term Track record of triple wins: $3.0
Slide 8: Business Overview
Business Overview Strong Leadership Positions and Significant Growth Opportunities
Slide 9: Leader in $4B+ Global Transcatheter Aortic Valve Replacement Market
Leader in $4B+ Global Transcatheter Aortic Valve Replacement Market Primary global growth drivers: indication expansion, therapy awareness, and technology advances Globally, diagnosis and treatment rates of AS remain low providing opportunity for low-double digit TAVR growth long-term Continued inve
Slide 10: $7B+ Estimated Global TAVR Opportunity by 2024
$7B+ Estimated Global TAVR Opportunity by 2024 2024 $7B+ Indication Expansion 2020 $4B+ Increasing 4 Awareness Technology We anticipate the global TAVR opportunity to grow at low double-digit CAGR through 2024 1/11/2021 10
Slide 11: Asymptomatic and Moderate Risk Clinical Trials
Asymptomatic and Moderate Risk Clinical Trials Expected to add significant growth beyond 2024 ~1.2M SAS Patients in the U.S. Asymptomatic SAS • Treating severe AS before symptoms may:1 • Beyond Severe Aortic o Prevent irreversible stenosis, we believe our myocardial damage TAVR therapy may benefit C
Slide 12: Our portfolio is constantly evolving
Our portfolio is constantly evolving SAPIEN 3 Ultra System SAPIEN 3 Pulmonic + Alterra Further elevates the performance benchmark of Pulmonic platform expands therapy for Next Generation TAVR SAPIEN 3 Congenital Heart Disease patients SAPIEN X4 + Clinical work expected to begin in U.S. in 2021 • Enh
Slide 13: TMTT focused on leading and transforming treatment for patients with mitral and tricuspid valve disease
TMTT focused on leading and transforming treatment for patients with mitral and tricuspid valve disease Three key value drivers: a portfolio of differentiated therapies, $3B global positive results from pivotal clinical trials and favorable real-world opportunity by 2025 clinical outcomes with signi
Slide 14: Diverse and complex patients need better treatment options
Diverse and complex patients need better treatment options DIVERSE P R E VA L E N T Mitral and tricuspid regurgitation are 10+% complex diseases people in the U.S. over 65 suffer from moderate or No two patients are alike severe MR/TR D E A D LY U N D E R T R E AT E D Untreated patients <2% have poo
Slide 15: TMTT is innovating a broad transcatheter portfolio
TMTT is innovating a broad transcatheter portfolio TRICUSPID MI TR AL Leaflet Repair PASCAL PASCAL Ace PASCAL PASCAL Ace Annular Reduction Cardioband Cardioband Valve Replacement EVOQUE SAPIEN M3 EVOQUE 1/11/2021 15
Slide 16: Building clinical evidence to transform standard of care
Building clinical evidence to transform standard of care 5 Pivotal Studies PASCAL PASCAL Functional MR PASCAL Tricuspid Degenerative MR SAPIEN M3 EVOQUE Mitral Tricuspid Strong evidence is central to expanding patient treatment 1/11/2021 16
Slide 17: Surgical Structural Heart brings leading innovation
Surgical Structural Heart brings leading innovation Current surgical structural heart market expected to grow mid- Extend leadership in single digits through 2026 $1.8B global surgical opportunity Extending our leadership as the partner of choice for cardiac surgeons with three product launches in 2
Slide 18: INSPIRIS is the world's leading aortic surgical valve
INSPIRIS is the world’s leading aortic surgical valve Trusted Platform Resilient Valve Class Magna Ease RESILIA • #1 implanted aortic surgical valve in the Proven PERIMOUNT Platform Resilient Tissue Technology U.S. and Japan, China launch in 2021 • Continuing adoption across U.S. and Europe • Provid
Slide 19: Our surgical portfolio strategy enables sustained growth through innovation
Our surgical portfolio strategy enables sustained growth through innovation KONECT RESILIA MITRIS RESILIA HARPOON Aortic Valved Conduit Surgical Mitral Valve Mitral Valve Repair System • First pre-assembled, ready-to- • Differentiating RESILIA tissue, • Standardizing mitral repair implant tissue con
Slide 20: Critical Care improving the quality of care for patients
Critical Care improving the quality of care for patients Critical Care Continuing to shift product mix towards Smart Recovery, which has highest growth potential of our product groups products benefit millions of patients every year Focusing on three key building blocks to advance Smart Recovery pat
Slide 21: Three Key Building Blocks for Smart Recovery
Three Key Building Blocks for Smart Recovery CAPITAL PLATFORM SENSORS SOFTWARE TECHNOLOGY T H G I S E R O F Hypotension Acumen Prediction 94 IQ Sensor Index (HPI) ForeSight Viewfinder Remote View HemoSphere Acumen IQ Cuff Edwards HPI Software Can Reduce “HPI was high and 10 minutes later there Intra
Slide 22: Financial Outlook
Financial Outlook
Slide 23: 2021 expected to be a year of significant growth and investment in our future
2021 expected to be a year of significant growth and investment in our future 2021 Expectations Mid-teens $2.00 - $2.20 Underlying net Adjusted sales growth EPS TAVR Surgical • Therapy expansion • Surgeon partnership • Technology advances • Leading pipeline • Geographic • Growth segment expansion fo
Slide 24: Edwards is poised for long-term value creation
Edwards is poised for long-term value creation Patient-Focused Culture motivates and guides our global team Sustainable Growth Large Populations organic revenue of under-served patients Innovative R&D Credibility and Trust produces breakthrough with clinicians, regulators, therapies and drives payor
Slide 25: P| PP TN
P| PP TN Re ND, ave Edwards Helping Patients is Our Life’s Work, and, now) pe?
Edwards Lifesciences — 39th Annual J.P. Morgan Healthcare Conference (January 2021) on 6ix